First-in-Human Study of KO-947 in Non-Hematological Malignancies

Summary

This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.

Timeline

Start

2017-04-06

Primary completion

2020-06-02

Completion

2020-06-02

Outcome

Outcome not reported

Stopped (Business): “Due to a strategic business decision Kura has stopped development of KO-947. Neither safety nor efficacy reasons were the cause of study termination.”

Drugs

Indications